The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

SPEAKER: [MUSIC PLAYING] [TYPING] If you have breast ... HER2 receptor protein. This will rule out certain kinds of protein-targeting therapy. They will also test whether your cancer cells have ...

To treat your advanced HER2 negative breast cancer ... or after to keep it from coming back. Some breast cancers also have receptors for the hormones estrogen and progesterone, which help cancer ...

The 2024 San Antonio Breast Cancer Symposium showcased significant advancements in hormone receptor-positive, HER2-negative breast cancer research, including findings from the PADMA study ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

This guide will help you understand how breast ... ER-negative (ER-) and PR-negative (PR-). This means your tumor does not use either of the hormones estrogen or progesterone to grow. These tumors ...

The EMBER-3 study introduced imlunestrant, an oral selective estrogen receptor degrader (SERD), as a potential treatment for hormone receptor–positive, HER2-negative metastatic breast cancer ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.

as the first HER2-directed therapy for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low, or HER2-ultralow metastatic breast cancer following progression on one ...